Skip to content

MDMA-Assisted Therapy for Posttraumatic Stress Disorder: A Mixed-Methods Case Study of a Participant of Color From an Open-Label Trial

Terence H. W. Ching, Monnica T. Williams, S. Reed, M. Kisicki, Julie B. Wang, B. Yazar-Klosinski, A. Emerson, R. Doblin

Journal of humanistic psychology February 10, 2022 DOI: 10.1177/00221678221076993 via Semantic Scholar

Summary

A mixed-methods case study examined whether a person of color with treatment-resistant PTSD would benefit from MDMA-assisted therapy (MDMA-AT) as much as participants in earlier, less diverse trials. The participant showed quantitative improvement in PTSD symptoms. An interpretative phenomenological analysis of therapy session transcripts revealed recurrent themes related to psychological mechanisms of symptom change, reduced PTSD symptoms, and additional positive and negative effects beyond symptom reduction. The authors discuss these themes and offer recommendations for addressing culturally relevant material during MDMA-AT.

Study at a glance

Characteristics Mixed-methods case study Open-label Case report Peer reviewed
Sample size 1
Population Participant of color with treatment-resistant PTSD from an open-label trial of MDMA-AT
Keywords Psychology Medicine Sociology
Citations 10
Key finding A participant of color with treatment-resistant PTSD showed quantitative improvement in symptoms and reported psychological mechanisms of change, reduced PTSD symptoms, and additional effects beyond symptom reduction during MDMA-assisted therapy.

Abstract

MDMA (±3,4-methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) was shown in previous clinical trials to have promising efficacy and safety for alleviating treatment-resistant posttraumatic stress disorder (PTSD). However, due to low ethnoracial diversity, the question remains as to whether ethnoracial minority participants would benefit similarly. Thus, a mixed-methods case study was conducted on a participant of color from an open-label trial of MDMA-AT for PTSD to provide a culturally informed lens on symptom recovery with this treatment approach. An additional aim was to elucidate mechanisms of change underlying this treatment for the participant. A case profile was provided, documenting quantitative improvement in PTSD symptoms. This was followed by an interpretative phenomenological analysis (IPA) of effects and mechanisms of action for this participant, based on integration session transcripts. Results of IPA indicated recurrent themes related to psychological mechanisms of symptom change, reduced PTSD symptoms, and additional effects (positive and negative) beyond PTSD symptom reduction. These themes were discussed and recommendations for attuning to culturally relevant material during MDMA-AT were provided.

Comments

No comments yet.

Log in to comment